Restoring the p53 ‘Guardian’ Phenotype in p53-Deficient Tumor Cells with CRISPR/Cas9
Highlights Limiting the CRISPR/Cas9-associated off-target effects is of major interest for increasing its clinical relevance. The original structure of the Cas9 nuclease has been modified